Form 4: Entera Bio CEO Awarded Substantial Equity Compensation

Entera Bio Ltd.'s Chief Executive Officer, Miranda Jayne Toledano, received significant equity awards, including restricted stock units and stock options, following shareholder approval on July 16, 2025.

Summary

• Miranda Jayne Toledano, Chief Executive Officer and Director of Entera Bio Ltd. (ENTX), was granted 136,842 ordinary shares as stock-settled restricted stock units (RSUs). These RSUs were approved by the Board on April 28, 2025, and by shareholders on July 16, 2025, awarded in lieu of her 2024 annual cash bonus. They vest ratably on a quarterly basis over one year, starting April 28, 2025.
• An additional 43,860 ordinary shares were granted as stock-settled RSUs to Ms. Toledano. These were also Board-approved on April 28, 2025, and shareholder-approved on July 16, 2025, in lieu of $100,000 of her 2025 base salary. They vest ratably on a quarterly basis over one year, starting April 1, 2025.
• Ms. Toledano also received a grant of 500,000 stock options with an exercise price of $2.28 per share. These options were approved by the Board on April 28, 2025, and by shareholders on July 16, 2025. They vest over a three-year period commencing April 28, 2025, with one-third vesting on the first anniversary and the remainder vesting ratably quarterly over the subsequent two years. The options expire on April 28, 2035.

Sentiment

Score: 7

Explanation: The sentiment is positive as the equity grants align the CEO's interests with shareholders and represent a commitment to performance-based compensation, which is generally viewed favorably. However, the potential for future dilution introduces a minor neutral element.

Positives

• The grant of significant equity compensation aligns the Chief Executive Officer's financial interests directly with the long-term performance and shareholder value of Entera Bio Ltd.
• Utilizing equity for compensation, including in lieu of cash bonus and a portion of base salary, conserves cash resources for the company.
• The vesting schedules for both RSUs (one year) and stock options (three years) encourage sustained performance and retention of key management.

Negatives

• The issuance of new shares for restricted stock units and the potential exercise of stock options could lead to future dilution for existing shareholders.
• The CEO accepting equity in lieu of a cash bonus and a portion of salary might indicate a strategic decision to preserve company cash, which could be interpreted as a sign of tight liquidity, though not explicitly stated.

Future Outlook

The document primarily details past compensation grants and their future vesting schedules, without providing broader forward-looking statements or guidance on company performance or strategy.

Industry Context

This filing is a standard disclosure of executive equity compensation, a common practice across industries, particularly in biotechnology, to incentivize leadership and align their interests with long-term company growth and shareholder returns.

Corporate Governance

Stakeholder Impact

• Shareholders: Potential for future dilution from the vesting and exercise of equity awards, but also benefit from increased alignment of CEO incentives with long-term company performance and value creation.
• Employees: No direct impact mentioned, but the compensation structure for the CEO may set a precedent or reflect the company's overall approach to executive incentives.
• Management (CEO): Receives substantial equity compensation, aligning personal wealth with company success and providing long-term incentives.

Next Steps

• Continued vesting of 136,842 restricted stock units quarterly over one year from April 28, 2025.
• Continued vesting of 43,860 restricted stock units quarterly over one year from April 1, 2025.
• Continued vesting of 500,000 stock options over a three-year period from April 28, 2025, with one-third vesting on the first anniversary and the remainder vesting quarterly over the subsequent two years.

Key Dates

Recommendation

Keywords

Entera Bio, ENTX, SEC Form 4, Equity Compensation, Restricted Stock Units, Stock Options, CEO Compensation, Insider Transaction, Executive Compensation, Shareholder Approval